(Q39033581)

8 September 2017

title

Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment (English)

1 reference

8 September 2017

Yong Ling

1

1 reference

8 September 2017

Xuemin Wang

2

1 reference

8 September 2017

Hongyan Zhu

3

1 reference

8 September 2017

Zhiqiang Wang

4

1 reference

8 September 2017

Chenjun Xu

5

1 reference

8 September 2017

Xinyang Wang

6

1 reference

8 September 2017

Li Chen

7

1 reference

8 September 2017

Wei Zhang

8

1 reference

8 September 2017

publication date

16 January 2014

1 reference

Archiv der Pharmazie - Chemistry in Life Sciences

8 September 2017

published in

1 reference

8 September 2017

volume

347

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

327-333

1 reference

The dark side of Ras: regulation of apoptosis

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Hyperactive Ras in developmental disorders and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Ras and Rho GTPases: a family reunion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Essential role for oncogenic Ras in tumour maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Dislodgment and accelerated degradation of Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Salirasib in the treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Mitigating heterocycle metabolism in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Guanidino anthrathiophenediones as G-quadruplex binders: uptake, intracellular localization, and anti-Harvey-Ras gene activity in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201300325

21 January 2018

Identifiers

DOI

10.1002/ARDP.201300325

1 reference

8 September 2017

1 reference